Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects

NCT07024212 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

MASLD

Interventions

DRUG: DR10624 Injection
DRUG: Placebo

Sponsor

Zhejiang Doer Biologics Co., Ltd.